VisionCare, Inc. Backgrounder

Updated June 2017

VisionCare, Inc. is a privately-held company focused on development, manufacturing, and marketing of implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. VisionCare's initial product (Implantable Miniature Telescope by Dr. Isaac Lipshitz) is a first-of-kind medical device for the most advanced form of AMD (end-stage AMD) and the leading cause of irreversible blindness in developed countries. The device has been granted approval by the FDA and Israel's Ministry of Health, and has also received a CE Mark in Europe.

According to the National Eye Institute, vision-impairing advanced forms of AMD (*'wet'* and *advanced 'dry'* AMD) affect approximately 2 million people in the U.S., and there are an additional 7 million individuals at risk of progressing to advanced AMD. Affected individuals are generally over 65 years of age. The high prevalence of AMD, in conjunction with limited treatment options, has created a major public health concern and an intense need for treatments that increase function and independence in this patient population.

There are currently no available medical treatments for dry AMD, and with efficacy limitations to AMD drugs, depending on how a patient's disease progresses, visual impairment eventually occurs. Ultimately, severe and untreatable vision loss affects both eyes in the end-stage form of AMD, creating a central blind spot that impairs the patient's ability to read, provide care for him/herself or others, or even recognize family and friends. VisionCare's telescope implant is designed to improve outcomes by providing patients with end-stage AMD the ability to regain central vision.

Implantable Telescope Technology

The telescope implant, about the size of a pea, is comprised of quartz glass micro-optics that renders an enlarged central vision image onto the healthy retinal areas surrounding the degenerated macula. The device is implanted behind the iris (colored-portion) in one eye during an outpatient surgical procedure. This essentially converts the eye into a telephoto system that reduces the impact of the blind spot by a factor of the telescope's magnification (approximately 2.5X) within a relatively wide field of view. Additionally, more central field visual information is available to viable retina photoreceptors. The new

central vision image allows patients to recognize images that were previously difficult or impossible to see (e.g., see facial features, read street signs, watch TV).

Prior to FDA approval, a clinical trial conducted across 28 leading U.S. ophthalmic centers demonstrated that the majority of patients gained at least 3 lines of visual acuity on the study eye chart and clinically meaningful quality-of-life improvements on the National Eye Institute Visual Function Questionnaire. To date, over 150 provider teams have implanted the device in over 600 patients.

Until now, the telescope implant treatment program, which is marketed under the brand name CentraSight®, was only available to patients 65 and over who have not had cataract surgery, a common procedure for seniors experiencing some vision loss. Now a new clinical trial launched in 2017 will evaluate the safety and effectiveness of the device for patients with end-stage AMD who have already had a cataract removed from the eye that will be implanted. If the trial is successful, it could potentially expand the eligibility for the procedure to many more people.

VisionCare is headquartered in Saratoga, Calif. with research facilities in Petah Tikva, Israel. For more information, please go to www.visioncareinc.net